National Planning Holding in Intercept Pharmaceuticals In (ICPT) Has Increased by $632,490; Main Street Research Has Raised Its Position in Abbvie (ABBV) by $8.57 Million as Market Valuation Rose

February 12, 2018 - By Ellis Scott

Main Street Research Llc increased its stake in Abbvie Inc (ABBV) by 217.65% based on its latest 2017Q3 regulatory filing with the SEC. Main Street Research Llc bought 97,386 shares as the company’s stock rose 6.17% with the market. The institutional investor held 142,131 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $12.63M, up from 44,745 at the end of the previous reported quarter. Main Street Research Llc who had been investing in Abbvie Inc for a number of months, seems to be bullish on the $178.74 billion market cap company. The stock increased 0.59% or $0.66 during the last trading session, reaching $111.96. About 2.42M shares traded. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since February 12, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

National Planning Corp increased its stake in Intercept Pharmaceuticals In (ICPT) by 20.89% based on its latest 2017Q3 regulatory filing with the SEC. National Planning Corp bought 10,905 shares as the company’s stock declined 12.60% while stock markets rallied. The institutional investor held 63,100 shares of the health care company at the end of 2017Q3, valued at $3.66 million, up from 52,195 at the end of the previous reported quarter. National Planning Corp who had been investing in Intercept Pharmaceuticals In for a number of months, seems to be bullish on the $1.37 billion market cap company. The stock increased 0.89% or $0.48 during the last trading session, reaching $54.69. About 513,063 shares traded. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has declined 14.52% since February 12, 2017 and is downtrending. It has underperformed by 31.22% the S&P500.

Among 23 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 12 have Buy rating, 3 Sell and 8 Hold. Therefore 52% are positive. Intercept Pharmaceuticals had 70 analyst reports since August 10, 2015 according to SRatingsIntel. Credit Suisse initiated the stock with “Outperform” rating in Wednesday, March 30 report. The firm has “Buy” rating by BMO Capital Markets given on Tuesday, September 12. On Friday, October 20 the stock rating was maintained by Needham with “Hold”. Wedbush maintained the stock with “Outperform” rating in Friday, December 30 report. Laidlaw downgraded the shares of ICPT in report on Friday, August 5 to “Sell” rating. Cantor Fitzgerald initiated it with “Sell” rating and $58 target in Wednesday, July 6 report. Morgan Stanley upgraded Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) on Friday, January 29 to “Equal-Weight” rating. The firm earned “Sell” rating on Tuesday, September 12 by Cantor Fitzgerald. Vetr upgraded Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) on Tuesday, September 22 to “Strong-Buy” rating. Cantor Fitzgerald upgraded the shares of ICPT in report on Thursday, November 2 to “Neutral” rating.

Investors sentiment decreased to 1.33 in Q3 2017. Its down 0.26, from 1.59 in 2017Q2. It is negative, as 33 investors sold ICPT shares while 30 reduced holdings. 30 funds opened positions while 54 raised stakes. 18.23 million shares or 10.01% less from 20.26 million shares in 2017Q2 were reported. Balyasny Asset Management Limited Liability Corporation accumulated 141,400 shares. Altrinsic Advisors Ltd Company holds 232,544 shares. Qs Ltd has invested 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Capital holds 0.02% or 1.85 million shares in its portfolio. Credit Agricole S A holds 0% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) or 17,000 shares. Deutsche National Bank Ag reported 211,076 shares. Css Limited Il reported 0.02% stake. Qvt Fin Limited Partnership holds 0.05% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) or 20,854 shares. Jane Street Limited Liability Company stated it has 31,596 shares or 0.01% of all its holdings. Edge Wealth Mngmt Limited Liability Co accumulated 300 shares. Tower Limited Liability Com (Trc) holds 778 shares or 0% of its portfolio. Sandy Spring National Bank owns 100 shares. Perceptive Advisors Ltd reported 90,000 shares stake. Point72 Asset Management Ltd Partnership reported 57,500 shares stake. Barclays Public Ltd Co holds 0% or 2,330 shares.

National Planning Corp, which manages about $1.20 billion US Long portfolio, decreased its stake in Seattle Genetics Inc (NASDAQ:SGEN) by 16,560 shares to 94,430 shares, valued at $5.14 million in 2017Q3, according to the filing. It also reduced its holding in Us Bancorp Del (NYSE:USB) by 12,009 shares in the quarter, leaving it with 8,617 shares, and cut its stake in Vanguard Bd Index Fd Inc (BSV).

Since September 11, 2017, it had 0 insider purchases, and 5 insider sales for $25.59 million activity. $705,655 worth of AbbVie Inc. (NYSE:ABBV) was sold by SALEKI-GERHARDT AZITA on Monday, September 11. Shares for $8.57M were sold by RICHMOND TIMOTHY J. on Monday, December 18. 145,510 shares valued at $14.07 million were sold by Schumacher Laura J on Thursday, December 14. $589,512 worth of AbbVie Inc. (NYSE:ABBV) shares were sold by Michael Robert A..

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 2 Sell and 9 Hold. Therefore 48% are positive. Abbvie Inc had 78 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Hold” rating by BMO Capital Markets given on Friday, April 28. UBS downgraded AbbVie Inc. (NYSE:ABBV) on Monday, September 25 to “Neutral” rating. As per Thursday, November 16, the company rating was maintained by BMO Capital Markets. The firm earned “Outperform” rating on Friday, February 5 by William Blair. Leerink Swann maintained AbbVie Inc. (NYSE:ABBV) on Monday, October 30 with “Outperform” rating. Argus Research maintained AbbVie Inc. (NYSE:ABBV) on Friday, February 2 with “Buy” rating. The firm has “Outperform” rating given on Friday, September 2 by Raymond James. The firm has “Hold” rating by Cowen & Co given on Friday, July 28. The rating was downgraded by Credit Suisse to “Neutral” on Monday, October 31. As per Tuesday, September 5, the company rating was maintained by Cowen & Co.

Investors sentiment decreased to 0.85 in 2017 Q3. Its down 0.15, from 1 in 2017Q2. It worsened, as 55 investors sold ABBV shares while 640 reduced holdings. 132 funds opened positions while 462 raised stakes. 1.06 billion shares or 1.89% more from 1.04 billion shares in 2017Q2 were reported. 135,442 are held by Bartlett And Comm Ltd Liability Corp. 40,042 are held by Matarin Mgmt Limited. Washington Tru Bankshares holds 1.67% or 118,477 shares in its portfolio. Department Mb Fin Bancorp N A holds 33,961 shares. Columbia Prtnrs L L C Investment accumulated 10,120 shares. Private Asset Management has 0.2% invested in AbbVie Inc. (NYSE:ABBV) for 1,231 shares. Wharton Business Grp Inc Limited Liability owns 42,475 shares for 0.4% of their portfolio. Bellecapital Limited owns 8,603 shares. South Dakota Invest Council stated it has 0.33% in AbbVie Inc. (NYSE:ABBV). 52,794 are owned by Conning. Insight Capital Rech & Mngmt Incorporated stated it has 1.28% of its portfolio in AbbVie Inc. (NYSE:ABBV). Exane Derivatives reported 30,799 shares stake. Becker Cap reported 0.02% of its portfolio in AbbVie Inc. (NYSE:ABBV). Great West Life Assurance Can has 0.31% invested in AbbVie Inc. (NYSE:ABBV) for 1.42 million shares. Meyer Handelman Comm has 101,981 shares for 0.41% of their portfolio.

Main Street Research Llc, which manages about $503.46 million and $619.66M US Long portfolio, decreased its stake in Tjx Companies Inc (NYSE:TJX) by 12,635 shares to 116,603 shares, valued at $8.60M in 2017Q3, according to the filing. It also reduced its holding in Bard C R Inc (NYSE:BCR) by 1,738 shares in the quarter, leaving it with 42,703 shares, and cut its stake in Facebook Inc (NASDAQ:FB).

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>